Search

News L. reuteri DSM 17938 in Infant Nutrition and Its Impact on the Gut Microbiota of Infants Born by Cesarean Section

The work of the Swiss-Greek team published in the Journal of Pediatric Gastroenterology and Nutrition focused on comparing the effect of infant formula containing Lactobacillus reuteri DSM 17938 on the microbiota of children born by cesarean section or vaginal delivery.

Source: GI, colic and microbiome 15. 5. 2020

News Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment

The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02, a biosimilar to bevacizumab, in patients with advanced non-small cell lung cancer.

Source: Oncological Treatment 15. 10. 2021

News How do patients perceive the treatment of ITP with romiplostim?

Romiplostim, along with eltrombopag and avatrombopag, belongs to the group of thrombopoietin receptor agonists (TPO-RA) used in the second line of treatment for immune thrombocytopenia (ITP). Its efficacy and safety are confirmed by numerous studies, but how do patients perceive its use and to what extent does it improve their quality of life? This was the focus of a review article by authors from the American Baylor College of Medicine.

Source: Immune Thrombocytopenia 15. 4. 2024

Články časopisu Global Allergy and Asthma European Network (GA²LEN) addresses the epidemic of allergy and asthma

Author of the article: Petr Panzner, Petr Čáp, Peter Burney, Torsten Zuberbier, Paul Van Cauvenberg, Jean Bousquet Source: Časopis lékařů českých | 1/2010 1. 1. 2010

News Current Options and Prospects for Effective Antiemetic Treatment in an Effort to Increase Adherence of Oncological Patients to Chemotherapy

Chemotherapy-induced nausea and vomiting (CINV) is strongly associated with treatment in the minds of many oncology patients, and its occurrence is rated as one of the most dreaded and stressful complications. For most patients, adherence to recommendations for antiemetic prophylaxis can successfully prevent the occurrence of CINV. A review article published last year by an international team of authors in the journal Future Oncology provides an overview of the current spectrum of options in CINV prophylaxis, focusing on the first combined preparation in this indication, containing the active substances netupitant and palonosetron.

Source: Antiemetic Therapy 31. 3. 2020

News Fixed combination tiotropium/olodaterol in regular clinical practice: What do patients say?

A non-interventional international study assessed the therapeutic benefits of the fixed combination of tiotropium/olodaterol in the treatment of chronic obstructive pulmonary disease (COPD) in real-world practice through a questionnaire filled out by patients.

Source: COPD 28. 5. 2021

News Dressing Solutions for Better Wound Care

Although wounds at different stages of healing require different types of treatment, the essential part of any dressing change is cleaning the wound and its surroundings from tissue debris and microorganisms and protecting it from reinfection. Modern dressing solutions facilitate easy cleaning and moisturizing of wounds. Effective treatment also brings clinical and economic benefits.

Source: Wound Healing 19. 3. 2023

News How to Most Effectively Delay Skeletal Events in Patients with Bone Metastases from Solid Tumors?

In a randomized Phase III study, the effectiveness of denosumab and zoledronic acid in preventing skeletal events in patients with multiple myeloma or solid tumors (excluding breast and prostate cancer) and bone metastases was evaluated. An ad hoc analysis of this study then involved only a subgroup of patients with solid tumors.

Source: Prevention of Bone Events 12. 9. 2022

News Lorlatinib as an Alternative to CNS Radiotherapy in Patients with NSCLC −⁠ Case Studies

Two remarkable case studies from authors at the Netherlands Cancer Institute Antoni van Leeuwenhoek in Amsterdam present patients with advanced NSCLC with metastatic CNS involvement. Treatment with crizotinib led to good control of pulmonary involvement but did not affect metastatic CNS involvement. The introduction of lorlatinib subsequently led to rapid improvement in neurological symptoms, which was also confirmed by CNS imaging.

Source: Genetic Profile and Treatment of NSCLC 10. 2. 2020

News Treatment of HFrEF with Sacubitril/Valsartan Does Not Have to Be the ‘Last Resort’

The TRANSITION study has provided evidence on the safety and efficacy of administering sacubitril/valsartan to patients after acute decompensation of chronic heart failure with reduced ejection fraction of the left ventricle (HFrEF). A recent sub-analysis of its results suggested that not only patients with a long-known diagnosis but also those with newly diagnosed HFrEF could benefit from the treatment if the possibility of its prescription in this indication arises.

Source: Chronic Heart Failure and Lipidology 9. 3. 2020

News Extension of Expected Lifetime When Treated with Empagliflozin in Patients with Type 2 Diabetes and Cardiovascular Disease

Reduction in expected lifetime is one of the main consequences of type 2 diabetes (T2DM). It is estimated that a 60-year-old patient with T2DM loses an average of 6–7 years of life compared to a person of the same age without T2DM. What impact does modern pharmacotherapy have on this adverse balance?

Source: Heart Failure 20. 8. 2021

News Perioperative Thromboprophylaxis in Elderly Patients

Thromboembolic disease (TED) is among the most common causes of death in hospitalized patients and also constitutes a significant portion of complications following surgical procedures. Without prophylaxis, thrombosis would develop in the perioperative period in almost 25% of patients. The risk of TED significantly increases with age, as does mortality. Over 21% of thrombotic complications occur in individuals over 65 years of age, and up to 16% of patients over 80 years old die shortly after being diagnosed with TED. It is crucial to focus on appropriate prevention and prophylaxis of TED in geriatric patients. However, studies have shown that thromboprophylaxis in hospitals in Europe and the USA is inadequate. Reasons may include concerns about increased bleeding during surgical procedures.

Source: Thromboprophylaxis 29. 4. 2021

News Pediatric Immune Thrombocytopenia Does Not Overlap with Adult ITP

Immune thrombocytopenia (ITP) is a highly heterogeneous disease characterized by various bleeding manifestations and different needs for treatment or likelihood of remission. The difference is accentuated in terms of the disease course between children and adult patients.

Source: Immune Thrombocytopenia 8. 6. 2020

News What is new in the treatment of atopic dermatitis and how are comorbidities affecting it?

Allergic rhinitis, conjunctivitis, bronchial asthma, or autoimmune diseases like alopecia, vitiligo, celiac disease, and idiopathic inflammatory bowel diseases –⁠ these are comorbidities that often trouble patients with atopic dermatitis (AD). Modern systemic treatments bring new hope to these patients. "The primary benefit of targeted treatment, especially for severe AD, is the mitigation or elimination of chronic inflammation and persistent itching, significantly improving the quality of life for patients," says Chief Physician MUDr. Miroslav Nečas, Ph.D., from the 1st Department of Dermatovenereology of MU and St. Anne's University Hospital in Brno.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 26. 6. 2023

News Prevalence and Incidence of Age-Related Macular Degeneration in Europe –⁠ Current Overview and Trend Analysis

A comprehensive review article by authors from Bonn, Germany, published late last year in the British Journal of Ophthalmology, provides current data and estimates of the incidence and prevalence of age-related macular degeneration in Europe. Here is a brief summary of the key findings from this latest analysis.

Source: Glaucoma 6. 2. 2020